Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747253 · ClinicalTrials.gov registry record · Phase 1
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
A Phase 1 study of Glioblastoma Multiforme and Brain Tumor, sponsored by Monteris Medical.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT00747253 is a Phase 1 study of Glioblastoma Multiforme and Brain Tumor that has completed, run by Monteris Medical. The registered enrollment target is 10 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00747253, a Phase 1 study of Glioblastoma Multiforme and Brain Tumor, has completed, sponsored by Monteris Medical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).
Conditions Studied
Interventions
- DEVICE AutoLITT system
Study Locations (2)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Cleveland Clinic Foundation, 9500 Euclid Ave - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00747253
The ClinicalTrials.gov registry entry for NCT00747253 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (90% lower). The listed sponsor is Monteris Medical, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which AutoLITT system is the first listed.
NCT00747253 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00747253 about?
NCT00747253 is a clinical study titled "Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors". The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).
What is the current status of trial NCT00747253?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2008-08. Estimated completion is 2010-04.
What conditions does trial NCT00747253 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Brain Tumor, Brain Cancer, Brain Neoplasm, Recurrent Glioblastoma Multiforme.
What interventions are being tested in trial NCT00747253?
The interventions under investigation include: AutoLITT system (DEVICE).
Who is sponsoring clinical trial NCT00747253?
This trial is sponsored by Monteris Medical, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00747253 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.